Shionogi & Co., Ltd. has obtained approval for an expanded pediatric dose and administration method of the anti-SARS-CoV-2 drug Zocova, extending its application to children aged 6 to under 12 years old weighing at least 20kg. Safety and blood concentration levels have been confirmed, broadening treatment options for COVID-19.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4507-20260619-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. has obtained approval for an expanded pediatric dose and administration method of the anti-SARS-CoV-2 drug Zocova, extending its application to children aged 6 to under 12 years old weighing at least 20kg. Safety and blood concentration levels have been confirmed, broadening treatment options for COVID-19.","jir_summary":"### Overview of Business Performance\nThis document does not present Shionogi & Co., Ltd.'s financial results but provides information on the newly approved expanded pediatric use of the anti-COVID-19 drug Zocova. Based on results from domestic Phase 3 clinical trials, safety and blood concentration levels have been confirmed, leading to the approval of a new 25mg tablet for children aged 6 and above but under 12 years old weighing at least 20kg. This expansion increases treatment options for COVID-19 and allows use regardless of the risk of severe illness.\n\n### Future Outlook and Impact\nThis approval represents a significant advancement in addressing public health challenges posed by COVID-19 and is part of Shionogi & Co., Ltd.'s efforts to promote comprehensive infectious disease care. Going forward, the company will continue to rapidly develop treatments and vaccines tailored to emerging variants and seasonal trends. The impact on consolidated performance for the fiscal year ending March 2027 is expected to be minimal.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Shionogi, #IR, #JapaneseStocks","jir_key_figures":"Approved pediatric application: age 6 to under 12 years, weighing at least 20kg\nAddition of new 25mg tablet approval\nNumber of domestic Phase 3 clinical trial registrations: 117 cases","jir_meta_title":"[Shionogi & Co., Ltd.] Additional Approval for Pediatric Use of COVID-19 | June 2026","jir_meta_description":"Shionogi & Co., Ltd. obtained approval for expanded pediatric use of the anti-SARS-CoV-2 drug Zocova. Confirmed safety and blood concentration levels, contributing to expanded treatment options.","jir_og_title":"[Shionogi & Co., Ltd.] Additional Approval for Pediatric Use of COVID-19 | June 2026","jir_og_description":"Shionogi & Co., Ltd. has obtained pediatric use approval for an anti-COVID-19 drug. Safety and blood concentration levels have been confirmed, expanding treatment options.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-66076","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n